Register
  • Community
    • Physicians
    • Editors
    • Experts
    • Code of conduct
    • Blog
    • Terms of Use
    • Privacy Policy
    • Sitemap
  • Company
    • About
    • Publications
    • Press
    • Careers
  • Programs
    • Journal Club
    • Targeted Topic
    • Clinical Trial
    • Tumor Board
  • Contact Us
  • Sign in

Pediatric Oncology

Myelodysplastic Syndromes   

Questions discussed in this category


How would you approach cytopenias 5 weeks after initial dosing in a young patient with MDS treated with Azacitadine as a bridge to transplant?
E.g. would you dose-reduce or continue at same dose? Baseline ANC was in the normal range
1 Answer available

Do you routinely send NGS testing from bone marrow samples in patients with unexplained cytopenia or cytoses?
For instance, if clonal hematopoiesis of indeterminate potential (CHIP) suspected 
1 Answer available

How would you optimally manage a patient with a MDS/MPN overlap syndrome who has both transfusion-dependent anemia and marked thrombocytosis?
Would this change with someone who has a history of thrombosis (e.g. DVT/PE, MI, CVA)? Would this change with someone who is more fit vs more frail?
1 Answer available
14170139129482


Papers discussed in this category


American journal of hematology, 2019-04
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".

Am J Hematol, 2019 Aug 07
The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia.

Related Topics in Pediatric Oncology

  • Lung Cancer
  • Breast Cancer
  • Head and Neck Cancers
  • Hematologic Malignancies
  • Radiation Oncology
  • Gynecologic Cancers
  • Palliation
  • Neuro-Oncology
  • Gastrointestinal Cancers
  • Genitourinary Cancers

Copyright © 2023 theMednet
All Rights Reserved.